OGD Recommends 'Biorelevant' Dissolution Testing Methods for Generic Drugs
This article was originally published in The Gold Sheet
Executive Summary
Speaking at the May 5 OGD/GPhA QbD workshop in Bethesda, Md., Anand noted that developing sound in vitro dissolution test systems is becoming more challenging for generic manufacturers with the growing complexity and uniqueness of the dosage forms on which they are working.